The Agency for Healthcare Research and Quality (AHRQ) has released for public comment its draft Technology Assessment, “Report on the Evidence Regarding Off-Label Indications for Targeted Therapies used in Cancer Treatment.” The document reviews the medical literature regarding 19 different drug/diseases indications that, at the time of their selection, were all off-label. The report concludes that for “some diseases, despite limited and/or ambiguous data, the use of an off-label indication may be a reasonable clinical decision.” The report suggests additional research in this area.  Comments will be accepted until November 16, 2009 (extended from initial November 9 deadline).